PT3116475T - Composições de inibidores de dopa-descarboxilase - Google Patents

Composições de inibidores de dopa-descarboxilase

Info

Publication number
PT3116475T
PT3116475T PT157317272T PT15731727T PT3116475T PT 3116475 T PT3116475 T PT 3116475T PT 157317272 T PT157317272 T PT 157317272T PT 15731727 T PT15731727 T PT 15731727T PT 3116475 T PT3116475 T PT 3116475T
Authority
PT
Portugal
Prior art keywords
decarboxylase inhibitor
inhibitor compositions
dopa decarboxylase
dopa
compositions
Prior art date
Application number
PT157317272T
Other languages
English (en)
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of PT3116475T publication Critical patent/PT3116475T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT157317272T 2014-03-13 2015-03-12 Composições de inibidores de dopa-descarboxilase PT3116475T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461952477P 2014-03-13 2014-03-13
US201461990967P 2014-05-09 2014-05-09

Publications (1)

Publication Number Publication Date
PT3116475T true PT3116475T (pt) 2020-12-15

Family

ID=53488380

Family Applications (2)

Application Number Title Priority Date Filing Date
PT201983715T PT3777833T (pt) 2014-03-13 2015-03-12 Composições do inibidor de dopa-descarboxilase
PT157317272T PT3116475T (pt) 2014-03-13 2015-03-12 Composições de inibidores de dopa-descarboxilase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT201983715T PT3777833T (pt) 2014-03-13 2015-03-12 Composições do inibidor de dopa-descarboxilase

Country Status (19)

Country Link
US (4) US10022320B2 (pt)
EP (3) EP3777833B1 (pt)
JP (2) JP6591995B2 (pt)
CN (1) CN106413754B (pt)
AU (1) AU2015228369B2 (pt)
BR (1) BR112016021034A8 (pt)
CA (1) CA2942244C (pt)
DK (2) DK3116475T3 (pt)
ES (2) ES2836325T3 (pt)
FI (1) FI3777833T3 (pt)
HR (2) HRP20231716T1 (pt)
HU (2) HUE064818T2 (pt)
IL (1) IL247668B (pt)
MX (1) MX2016011837A (pt)
PL (2) PL3777833T3 (pt)
PT (2) PT3777833T (pt)
RS (1) RS65060B1 (pt)
RU (1) RU2684105C2 (pt)
WO (1) WO2015136538A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3192500B1 (en) 2009-05-19 2020-12-02 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
CN103442693A (zh) 2010-11-15 2013-12-11 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
FI3777833T3 (fi) 2014-03-13 2024-01-03 Neuroderm Ltd Dopa-dekarboksylaasin estäjän koostumuksia
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
WO2017059091A1 (en) 2015-09-30 2017-04-06 Duke University Contrast agents for magnetic resonance imaging
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
CA3117983A1 (en) 2018-11-15 2020-05-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
CN113396897B (zh) * 2021-07-26 2022-06-07 苏州华测生物技术有限公司 一种稳定生物基质中卡比多巴/左旋多巴的方法

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
AU6889274A (en) 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3936495A (en) 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (ja) 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
JPS56115749A (en) 1980-02-18 1981-09-11 Sagami Chem Res Center Dopa derivative
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
ES2042520T3 (es) 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4684666A (en) 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
IT1226902B (it) 1988-07-12 1991-02-21 Mini Ricerca Scient Tecnolog Processo per la sintesi del levodopa
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
CA2058975C (en) 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2143070C (en) 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
DK0828513T3 (da) 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
IL119417A (en) 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6245917B1 (en) 1998-03-20 2001-06-12 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
BR9910508B1 (pt) 1998-05-15 2012-01-24 preparações farmacêuticas estabilizadas de derivados de ácido gama-aminobutìrico.
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
IL159812A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
JP4850390B2 (ja) 2001-10-19 2012-01-11 アイデックス ラボラトリーズ インコーポレイテッド 薬理学的に活性な化合物の制御送達のための注射用組成物
US6916813B2 (en) 2001-12-10 2005-07-12 Bristol-Myers Squibb Co. (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
ES2189682B1 (es) 2001-12-11 2004-04-01 Laboratorios Del Dr. Esteve, S.A. Preparacion bebible que comprende ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea.
EP1496868A1 (en) 2002-04-11 2005-01-19 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of carbidopa and levodopa
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
KR20050072432A (ko) 2002-10-10 2005-07-11 모르포켐 악티엥게셀샤프트 퓌르 콤비나토리셰 케미 항균 활성을 갖는 신규한 화합물
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
RU2426590C2 (ru) 2003-07-18 2011-08-20 Бакстер Интернэшнл Инк. Способы изготовления, применение и композиции небольших сферических частиц, приготовленных регулируемым фазовым разделением
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
JP5160786B2 (ja) * 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
AU2004285532A1 (en) 2003-10-31 2005-05-12 Alza Corporation Administration of levodopa and carbidopa
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
SI1797109T1 (sl) 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
US20060241183A1 (en) 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
EP1809283A2 (en) 2004-10-01 2007-07-25 The Research Foundation Of State University Of New York Morphine and morphine precursors
CA2611114C (en) 2005-06-08 2014-09-23 Orion Corporation An entacapone-containing oral dosage form
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101636145B (zh) 2006-05-31 2014-04-23 雅培产品有限公司 长期24小时经肠给予左旋多巴/卡比多巴
US20080139655A1 (en) 2006-09-08 2008-06-12 Drugtech Corporation Sustained-release composition and method of use thereof
US8058243B2 (en) 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
US8563013B2 (en) 2007-04-06 2013-10-22 Janssen Biotech, Inc. Systems and methods for delivering a fluid drug
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
NZ587168A (en) * 2008-02-06 2011-06-30 Wockhardt Research Center Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
CN101669925B (zh) 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
WO2010055133A1 (en) 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
EP3192500B1 (en) 2009-05-19 2020-12-02 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
CN103442693A (zh) 2010-11-15 2013-12-11 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
DK2640370T3 (en) 2010-11-15 2018-06-25 Neuroderm Ltd COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE RESOURCES
WO2012079072A2 (en) 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
TR201204839A2 (tr) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
BR112014030265A2 (pt) 2012-06-05 2017-06-27 Neuroderm Ltd composição farmacêutica líquida ou semissólida e método para tratar uma doença ou distúrbio neurológico ou de movimento.
US20150217046A1 (en) 2012-06-05 2015-08-06 Synagile Corporation Dosing regimens for subcutaneously infusible acidic compositions
PT2968218T (pt) * 2013-03-13 2021-09-24 Neuroderm Ltd Combinação para tratamento da doença de parkinson
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
FI3777833T3 (fi) 2014-03-13 2024-01-03 Neuroderm Ltd Dopa-dekarboksylaasin estäjän koostumuksia
EP4186510A1 (en) 2014-10-21 2023-05-31 AbbVie Inc. Intermediates and process for preparing l-dopa diphosphate
CN108495617A (zh) 2015-11-24 2018-09-04 纽罗德姆有限公司 包含左旋多巴酰胺的药物组合物和其用途
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
WO2019038638A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA
WO2019038637A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd FORMS OF CRYSTALLINE SALT OF LEVODOPA AMIDE AND METHODS OF MAKING AND USING THEM
AR112683A1 (es) 2017-08-21 2019-11-27 Neuroderm Ltd Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende

Also Published As

Publication number Publication date
BR112016021034A2 (pt) 2017-08-15
RU2684105C2 (ru) 2019-04-04
EP4299128A3 (en) 2024-04-17
HUE052642T2 (hu) 2021-05-28
EP3116475B1 (en) 2020-11-04
MX2016011837A (es) 2017-04-27
AU2015228369B2 (en) 2020-05-21
US20210038505A1 (en) 2021-02-11
US10022320B2 (en) 2018-07-17
ES2836325T3 (es) 2021-06-24
PL3116475T3 (pl) 2021-02-08
CN106413754B (zh) 2019-11-29
EP3777833A1 (en) 2021-02-17
US20230240980A1 (en) 2023-08-03
AU2015228369A1 (en) 2016-10-27
RS65060B1 (sr) 2024-02-29
HRP20231716T1 (hr) 2024-03-15
DK3777833T3 (da) 2023-12-18
CN106413754A (zh) 2017-02-15
CA2942244A1 (en) 2015-09-17
US20190151233A1 (en) 2019-05-23
JP6770158B2 (ja) 2020-10-14
PL3777833T3 (pl) 2024-03-25
PT3777833T (pt) 2024-01-09
BR112016021034A8 (pt) 2021-06-29
IL247668A0 (en) 2016-11-30
WO2015136538A1 (en) 2015-09-17
US10624839B2 (en) 2020-04-21
US20150352212A1 (en) 2015-12-10
EP3116475A1 (en) 2017-01-18
EP3777833B1 (en) 2023-10-18
JP2017507973A (ja) 2017-03-23
RU2016135952A (ru) 2018-04-13
JP6591995B2 (ja) 2019-10-16
JP2020011977A (ja) 2020-01-23
RU2016135952A3 (pt) 2018-09-12
EP4299128A2 (en) 2024-01-03
IL247668B (en) 2020-09-30
HUE064818T2 (hu) 2024-04-28
CA2942244C (en) 2022-08-23
HRP20201948T1 (hr) 2021-01-22
DK3116475T3 (da) 2020-12-07
FI3777833T3 (fi) 2024-01-03
ES2967693T3 (es) 2024-05-03

Similar Documents

Publication Publication Date Title
IL247668A0 (en) Preparations that include dopa decarboxylase inhibitors
IL246362A0 (en) Novel glutaminase inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
SG11201704936SA (en) Corrosion inhibitor compositions for acidizing treatments
HUE046273T2 (hu) Ciklopropilaminok mint LSD1 inhibitorok
HUE045725T2 (hu) Ciklopropilaminok mint LSD1 inhibitorok
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
EP3347333C0 (en) POLYMERIZATION INHIBITOR COMPOSITIONS
GB201403536D0 (en) Inhibitor compounds
ZA201704301B (en) Microencapsulated nitrification inhibitor compositions
LT3227325T (lt) Selektyvaus il-6-trans signalinio kelio inhibitoriaus kompozicijos
HUE050027T2 (hu) Antioxidáns készítmények
IL247921A0 (en) Glutaminase inhibitor compounds, preparations containing them and their uses
GB201411802D0 (en) Effervescent compositions
IL251479A0 (en) components
GB201408167D0 (en) Compositions
GB201420306D0 (en) Compositions
GB201406542D0 (en) Intumescent compositions
SG11201610860UA (en) Sweetener compositions
GB201401005D0 (en) Inhibitor
GB201501779D0 (en) NONOate compositions
GB201411470D0 (en) Effervescent compositions
GB201419849D0 (en) Compositions
GB201406863D0 (en) Compositions comprising variegin